Last updated: February 23, 2026
What is the drug identified by NDC 42806-0147?
NDC 42806-0147 corresponds to Nivestim, a biosimilar version of Neupogen (filgrastim). It is administered to decrease the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy.
What is the current market landscape for filgrastim biosimilars?
The biosimilar segment for granulocyte-colony stimulating factor (G-CSF) products like filgrastim has expanded significantly. Key market actors include:
- Neupogen (originator): Dominated the market before biosimilar entry.
- Bosulif (biosimilars): Several biosimilars entered US and EU markets, with Nivestim among the first wave.
- Regulatory approvals: Biosimilars approved primarily in the US since 2017, with increasing market acceptance.
In 2022, biosimilar sales in the US for G-CSF products totaled approximately $1.2 billion. The biosimilar share increased from under 10% in 2018 to over 50% in 2022, driven by cost advantages and regulatory support.
Geographical markets
| Region |
Market Share of Biosimilars (2022) |
Notable Biosimilars |
| United States |
55% |
Nivestim, Zarxio |
| European Union |
65% |
Nivestim, Tevagrastim |
| Asia-Pacific |
40-55% |
Multiple local entrants |
What are the pricing trends for Nivestim?
Pricing analysis indicates a downward trend driven by biosimilar competition:
- Average wholesale price (AWP): In the US, the AWP for Nivestim ranges from $650 to $750 per 480 mcg/1.6 mL dose.
- Price discounts: Biosimilars are typically priced at 15-25% lower than the originator, Neupogen.
- Reimbursement: Medicare and private payers increasingly favor biosimilars, incentivizing formulary placement and further price reductions.
In European markets, prices are often lower, with discounts of 30-50% relative to originator prices due to tendering processes.
What are the projections for the market size and pricing over the next five years?
Market size projections:
| Year |
US Biosimilar G-CSF Market (USD Billions) |
Global Biosimilar G-CSF Market (USD Billions) |
| 2023 |
1.3 |
2.4 |
| 2025 |
2.2 |
4.1 |
| 2027 |
3.0 |
6.5 |
| 2030 |
4.2 |
9.8 |
Assumptions: Continued biosimilar adoption driven by policies, price sensitivity, and expanding indications.
Price projections:
- US: Biosimilar prices are expected to stabilize at around $550-$700 per dose by 2025, with potential reductions to $500-$600 by 2030 as competition intensifies.
- Europe: Prices are forecast to decline by an additional 10-15% over the next five years due to tendering and price negotiations.
Key factors influencing projections:
- Regulatory pathway approvals for additional biosimilars.
- Patent expirations of originator (Neupogen) in major markets.
- payer and hospital formulary adoption policies.
- Innovations in biosimilar manufacturing to reduce costs.
What is the competitive landscape?
Major players include:
- Sandoz: First biosimilar (Zarxio) approved in 2015.
- Novartis: Through its Sandoz unit, aggressively expanding biosimilar portfolio.
- Biocon / Mylan: Entered with remicade biosimilars, expanding into G-CSF.
What risks could impact future pricing and market share?
- Regulatory delays: Denials or delays in biosimilar approvals reduce market growth.
- Patent litigation: Originator patent defenses could restrict biosimilar penetration.
- Physician acceptance: Prescriber primacy for originators may slow biosimilar adoption.
- Pricing policy shifts: Payer resistance to further price declines could stabilize or increase prices.
Key Takeaways
- Nivestim operates within a rapidly expanding biosimilar G-CSF market, with increasing competition and downward pressure on pricing.
- The market is expected to grow substantially through 2030, driven by policy, patent expiries, and cost pressures.
- US biosimilar prices are projected to decline to approximately $500-$600 per dose by 2030, with persistent uptake growth.
- Competition includes multiple biosimilars and originator products, influencing price and market share.
- Long-term market dynamics depend on regulatory environment, physician acceptance, and payer policies.
FAQs
1. How does Nivestim compare with other biosimilar G-CSFs in price and efficacy?
Nivestim is priced approximately 15-25% below Neupogen. Clinical efficacy aligns with the originator, and biosimilar approval is contingent on demonstrating biosimilarity in safety, potency, and immunogenicity.
2. What are the primary drivers for biosimilar adoption in the US?
Cost savings, payer mandates favoring biosimilars, patent expirations of originator products, and regulatory incentives.
3. Which markets present the greatest growth opportunities for Nivestim?
The US, Europe, and Asia-Pacific regions show the greatest growth potential due to expanding indications and increasing biosimilar acceptance.
4. What are the barriers to biosimilar market penetration for Nivestim?
Physician skepticism, originator patent litigation, reimbursement challenges, and limited clinician experience with biosimilars.
5. How might future policies impact biosimilar pricing?
Potential for increased rebate and formulary restrictions favoring biosimilars could lead to further price reductions and market share gains.
References
[1] IQVIA Institute. (2022). The Growing Impact of Biosimilars.
[2] FDA. (2022). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2022). World Market Forecast for Biosimilar G-CSF.
[4] Medicaid and Medicare Policy Updates. (2023). Biosimilars and Reimbursement Strategies.
